Hospiton.Rare diseases

Event targets: students, professionals, and enthusiasts of different fields – medicine, nursing, engineering, IT, management, design, social services and other fields, as well as patients, their relatives, innovation development enthusiasts. Everyone who wants to solve real challenges in the field of health together – to create solutions that facilitate the treatment of patients with rare diseases and the daily life of patients and their relatives.

Medical or other field knowledge is not mandatory. Different competences allows us to discover non-standard solutions to challenges together.

Hospiton 2022 challenge – RARE DISEASES:

1. Identification and education. New diagnostic methods, use of data and dissemination of information – education of the public (from children to teachers) and specialists, raising awareness, improving communication between doctors, patients and relatives.
2. Effective therapy. Use of data, precision medicine, personalized treatment, use of new technologies, treatment methods, drug development.
3. Quality of life. Solutions for everyone – patient, relative, doctor – dealing with rare diseases. Treatment monitoring, adaptation of the environment to the patient and his relatives, help and support to the relative, family, patient.
   Opportunities: During the hackathon, participants get to know the current challenges of rare disease treatment. Teams or individual participants put together in teams, create innovative solutions that solve challenges together. Access to patients and their relatives to understand the problems they are experiencing better, as well as the help and advice of mentors from various fields and special training will help you in your journey. The culmination of the event is the presentation of the teams’ solutions to the jury and the announcement of the winners of Hospiton.Rare diseases.

Date: November 18-20.
Event location: LSMU “Santakos” Valley, The Centre for Advanced Pharmaceutical and Health Technologies, Sukilėlių pr. 13, Kaunas
Registration: here 
More information: on Facebook and [email protected] [email protected]